US 10226468
Quinazolines and azaquinazolines as dual inhibitors of RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/mTOR pathways
granted A61KA61K31/5377A61K45/06
Quick answer
US patent 10226468 (Quinazolines and azaquinazolines as dual inhibitors of RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/mTOR pathways) held by Asana BioSciences, LLC expires Mon Mar 07 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Asana BioSciences, LLC
- Grant date
- Tue Mar 12 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Mar 07 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 35
- CPC classes
- A61K, A61K31/5377, A61K45/06, A61P, A61P35/00